Article Based on PREV's Pain Management Peptides Program Vancouver, British Columbia--(Newsfile Corp. - May 9, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that the British Journal of Pharmacology (the "BJP"), published an article on April 29, 2022, on the design and development of its non-addictive analgesic program ("Analgesic Program") under the running title, "Short dynorphin-like peptide agonists for kappa opioid receptors" click here to see the report. The article has undergone full independent peer review.
The Analgesic Program, which commenced in July 2018 to discover and develop peptide-based therapeutics for moderate to severe pain and inflammation, and was successfully completed in March 2021.
The BJP is the leading international general pharmacology journal published by the British Pharmacological Society. It publishes high-quality original research and authoritative reviews, addresses topical pharmacology issues, and is committed to transparency and scientific rigour.
The class of compounds, peripheral Kappa opioid receptor (KOPr) agonists, are considered potential analgesics without the dose-limiting central nervous system-mediated side effects. The potency and duration of action of peptides identified in the study were comparable to the clinical standard morphine, in-vivo.
PreveCeutical's Chair and Chief Executive Officer, Mr. Stephen Van Deventer, stated, "Having an independent peer reviewed article from PreveCeutical's program and having it published in the prestigious BJP is a big milestone for our non-addictive analgesic program. We will continue to assess potential partnerships to develop safer analgesics with our patent-pending peptides. Therapies based on these potentially non-addictive peptides will be important in addressing the current opioid crisis."
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.
With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.
The Company is currently in the research and development stage for dual gene curative and preventive therapies for diabetes and obesity.
For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations ir@preveceutical.com